Spero Therapeutics ($SPRO) Stock Hub: Utebzi Approved, SP001 Licensed and Runway Guided Into 2H 2029

01 Scenario framework: evidence before price targets

Spero is now two businesses inside one small market capitalization: a partnered, approved antibiotic whose economics flow through GSK and, since July 2026, through a royalty-backed note structure; and an early immunology program that has to be built in a new disease.

No target price is assigned; the scenarios are not probabilities or recommendations. The most informative near-term observation is whether GSK makes Utebzi available by the end of 2026, because that starts both the milestone sequence and the commercial evidence.

What Would Falsify This Reading

The reading in these pages is that Spero is a funded but encumbered reset: an approved, partnered antibiotic whose economics serve the notes first, and an anti-CD40L antibody that still has to prove itself in IgG4-related disease. These are the observations that would make that reading wrong, in either direction.

• Utebzi not available by December 31, 2026. A slip into 2027 without explanation would delay the $51.0 million first-sale milestone and every later commercial milestone, and weaken the case for an early pay-down of the notes.
• ATM sales disclosed in the third-quarter 10-Q. Material sales at current prices soon after guiding a runway into 2029 would show the ATM is a funding source, not a precaution.
• No U.S. IND for SP001 by July 8, 2027. The Innovent agreement requires it within 12 months of July 8, 2026, subject to extensions; missing it, or a clinical hold, would undercut the second-quarter 2027 Phase 2 target.
• A differently designed Phase 2. A ClinicalTrials.gov registration materially different from the open-label, roughly 30-patient design with the IgG4-RD Responder Index at week 24 would change timeline and read-out value.
• GSK sales near the $200 million annual threshold. The sales milestones would start and the notes would amortize much faster, making the cautious reading of the waterfall too conservative.

None of these is a prediction. They are the observations that would make the reading above wrong, listed so that a reader can check them rather than take it on trust.

02 Current research position

As of October 2, 2026, Utebzi is FDA-approved and partnered with GSK, with U.S. availability guided by the end of 2026; SP001 is licensed, with a Phase 2 in IgG4-related disease targeted for the second quarter of 2027; and the $300 million shelf with its $100 million ATM has been usable since September 10, 2026, which is capacity, not cash raised.

The June 30 cash of $50.8 million predates the July transactions: the $105 million financing, the $35 million owed to Innovent and the $1.0 million approval milestone paid to Meiji. The runway guidance into the second half of 2029 is a forward-looking estimate. No patient with IgG4-related disease has yet received SP001 in a disclosed study. The third-quarter report has not been dated; in 2025 it came on November 13.

03 Investment summary and central debate

The debate is no longer about FDA approval. It is about how much of the Utebzi economics remain for common shareholders after the July financing, and whether SP001 can be worth more than the cash and time it will consume. At the October 1, 2026 close of $1.26, basic equity value was about $73.4 million on 58,234,827 shares.

A careful comparison with liquidity adjusts for four items: the financing proceeds were reduced by 1.5% at closing to about $103.4 million; the notes are a claim on future GSK proceeds growing at 10% a year; the $35 million Innovent upfront is a real outflow; and research spending will rebuild from a low base of $3.4 million in the second quarter.

04 How the SPRO thesis changed

The timeline below lists the verified steps that turned Spero from an anti-infective developer waiting for an FDA decision into an immunology company with a partnered antibiotic in its rear-view mirror.

05 Utebzi: approval is real, commercialization is the new test

The FDA approved Utebzi (tebipenem pivoxil) on June 17, 2026 for adults with complicated urinary tract infections, including pyelonephritis, caused by susceptible Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae species complex, Klebsiella oxytoca and Enterococcus faecalis, in patients who have limited or no alternative oral treatment options. GSK describes it as the first and only oral carbapenem antibiotic in the United States. The restricted population matters: Utebzi is not a broad first-line oral antibiotic.

PIVOT-PO randomized hospitalized adults to oral tebipenem pivoxil 600 mg every six hours or intravenous imipenem-cilastatin 500 mg every six hours for seven to ten days. The primary endpoint was overall response, a composite of clinical cure and microbiological eradication at the test-of-cure visit, assessed for non-inferiority with a 10% margin. According to GSK, overall success was 58.5% (261 of 446) with tebipenem pivoxil and 60.2% (291 of 483) with imipenem-cilastatin, an adjusted difference of −1.3% (95% confidence interval −7.5% to 4.8%). The lower bound of the interval, −7.5%, stays above the −10% margin, which is what a non-inferiority claim requires.

Safety was described by GSK as generally similar to imipenem-cilastatin and other carbapenems; the most frequent adverse events, at an incidence of at least 3%, were diarrhea and headache, all mild or moderate and non-serious. The label carries the class precautions, including Clostridioides difficile-associated diarrhea, and the pivoxil moiety brings carnitine-related considerations.

The commercial rationale is a step-down from intravenous to oral therapy. GSK cites more than 3 million complicated urinary tract infections a year in the United States, treatment failure in up to 34% of patients and more than $6 billion a year in healthcare costs; those are partner figures, not a forecast of Utebzi sales.

Regulatory protection is a further asset. The 2025 Form 10-K states that tebipenem holds Qualified Infectious Disease Product designation for complicated urinary tract infection, and that approval in a QIDP indication entitles the product to a five-year extension of any non-patent exclusivity, such as the five-year new chemical entity period.

FDA · GSK approval release · 2025 Form 10-K

06 GSK economics and the royalty-financing waterfall

Spero licensed tebipenem to GSK in September 2022 for all territories except Japan and other Asian countries previously licensed to Meiji Seika Pharma; GSK carries commercial supply and commercialization. After the payments listed in the timeline above, the remaining milestones in the second-quarter Form 10-Q are:

Royalties are the less visible part of the deal, and the 10-Q is precise about them: GSK pays 1% on annual net sales up to $750 million, then high single-digit rates above $750 million and low double-digit rates above $1 billion. On the other side, Spero’s own license from Meiji obliges it to pay Meiji royalties of 1% of net sales of licensed products, and Spero paid Meiji a $1.0 million approval milestone in July 2026. On the face of the two disclosures, the royalty received and the royalty owed are both 1% at the sales levels a new hospital antibiotic usually reaches in its early years; the filings do not present a net figure. The value of Utebzi to Spero sits in the milestones.

In July 2026 Spero turned part of that stream into cash. Through two special-purpose subsidiaries it issued $105 million of senior secured notes to affiliates of HealthCare Royalty (HCRx), a business of KKR, and sold them, under a separate agreement, 65% of the GSK proceeds arising after the notes are repaid. The notes were issued with a $3.15 million original issue discount and the purchase price of the residual interest was $1.575 million, which together reduced the $105 million of gross proceeds by 1.5%. The notes accrue 10% a year; interest not paid from available GSK proceeds is added to principal every quarter. They mature nine years after July 8, 2026 and are generally payable solely from the pledged GSK proceeds, which the agreements define as certain milestone and royalty payments under the GSK license.

Spero gives a limited-recourse guaranty, capped except in very limited circumstances, and services the arrangement for its subsidiaries. In an event of default, the noteholders can accelerate and foreclose on the collateral, which consists of substantially all assets of the two subsidiaries, including the pledged GSK payments; recourse to Spero itself runs through the capped limited guaranty.

Form 10-Q, license and subsequent-events notes · July 2026 Form 8-K

07 The waterfall in numbers: what the launch milestones can and cannot do

The filings give the terms but not a payment schedule, so the arithmetic below is Merlintrader’s, built only on disclosed figures and labeled assumptions. It answers one question: how quickly can the GSK payments retire the notes, and therefore when does Spero’s 35% begin to matter?

Assume interest is capitalized at 2.5% a quarter, the simplest reading of 10% a year added to principal quarterly, and that no GSK payment arrives. The balance would be about $110.3 million after two quarters, $115.9 million after one year, $127.9 million after two years and $141.2 million after three years. Compounding quarterly, the effective annual rate is about 10.4%.

Now add the launch milestone. If the first U.S. sale occurred around the turn of the year and the full $51.0 million were applied to the notes, the balance would fall from roughly $110.3 million to about $59.3 million. Eight more quarters of capitalized interest would take it to about $72.3 million by the second anniversary of the launch, when a further $25.0 million is due, leaving about $47.3 million. The European milestone of $25.0 million would help, but its timing depends on GSK’s European filing, which has not been dated publicly. At 1%, $100 million of annual sales adds about $1 million a year.

In Spero’s accounts, GSK payments in 2027 and 2028 are therefore more likely to appear as a lower note balance than as new cash; the retained 35% is real but probably distant.

08 SP001: a Phase 2-ready anti-CD40L reset

SP001, Innovent’s IBI355, is a third-generation, fully humanized, Fc-silent IgG1 monoclonal antibody against CD40 ligand, a signal on activated T cells that sits upstream of B-cell activation, antibody class switching, germinal-center formation and the activation of antigen-presenting cells. Blocking CD40L is attractive in autoimmunity because it acts above several downstream pathways at once without depleting B cells.

The pathway has a history. First-generation anti-CD40L antibodies such as ruplizumab were associated with thrombotic events, attributed to the interaction of their Fc region with FcγRIIa receptors on platelets. Second-generation agents such as dazodalibep avoided the problem by dropping the antibody Fc altogether, at the cost of a shorter half-life. SP001 is engineered with a silenced Fc that, according to Spero, removes Fc-receptor and complement binding while keeping FcRn interaction, which supports an IgG-like half-life and monthly dosing. That is a design rationale supported by early data, not yet a clinical guarantee.

Spero holds exclusive worldwide rights outside mainland China, Hong Kong, Macau and Taiwan, where Innovent keeps the rights and plans its own Phase 2 in Sjögren’s disease by early 2027. The license terms, all from the July 2026 Form 8-K and the Q2 10-Q, are:

• Upfront: $35.0 million owed to Innovent.
• Milestones: up to about $1.05 billion on development, regulatory and commercial events; contingent obligations, not debt or a forecast.
• Royalties: tiered from a high single-digit to a mid-teen percentage of net sales, for the longest of patent life, regulatory exclusivity or 11 years from first sale in each country.
• Diligence: commercially reasonable efforts to develop and commercialize in the U.S. and in at least one of France, Germany, Italy, Spain, the U.K. or Japan; a U.S. IND within 12 months of July 8, 2026, subject to extensions for specified justifiable delays.
• Exclusivity: for five years, neither party may clinically develop or commercialize another CD40L-targeting antibody in Spero’s territory.
• Exit: Spero may terminate on 90 days’ notice before first sale.

Form 8-K, Item 1.01 · July 14, 2026 license release

09 What the human data do, and do not, show

Innovent ran two Phase 1 studies in healthy volunteers, single and multiple ascending dose, and a Phase 1b multiple-ascending-dose study in patients with primary Sjögren’s disease, presented as a poster at the EULAR 2026 Congress. The Phase 1b was double-blind and placebo-controlled, conducted in China, with three intravenous cohorts of 7.5, 15 and 30 mg/kg every four weeks for four doses, eight active patients per cohort and six on pooled placebo. Safety was the primary endpoint; ESSDAI and ESSPRI were exploratory.

The safety table in Spero’s July presentation shows adverse events in 79.2% of the 24 SP001 patients and 100% of the six on placebo; upper respiratory tract infection in 50.0% versus 33.3%; hyperlipidemia in 16.7% in both groups; and no serious adverse event in any arm. Spero also reports linear pharmacokinetics, a half-life of about 28 days and a low rate of anti-drug antibodies.

On efficacy, every dose group improved on ESSDAI, ESSPRI and rheumatoid factor while placebo moved the other way, as charted in the presentation. In the subgroup with moderate-to-severe disease (ESSDAI of 5 or more) the placebo-adjusted ESSDAI change charted for SP001 is close to −4.5 points at week 16 in five patients, against a placebo group that included only three such patients. Spero itself notes that cross-study comparisons are inherently limited.

The disclosed data justify a Phase 2 test; they do not establish efficacy or a best-in-class profile. ClinicalTrials.gov lists the Sjögren’s study as NCT06484855, with 30 participants, primary completion on June 21, 2025 and study completion on July 25, 2025. Those dates describe the earlier study, not an IgG4-RD read-out.

July 2026 investor presentation (SEC exhibit 99.3) · NCT06484855

10 Planned IgG4-RD Phase 2: the next value-creation test

Spero’s July presentation outlines an open-label study with two SP001 dose groups of about 15 patients each, a 24-week treatment period and an optional long-term extension to week 52. Eligible patients would have IgG4-RD with more than one organ involved over time and active disease in at least one organ at enrollment; patients needing steroids would follow a protocol with a four- or eight-week steroid taper. The primary endpoint is efficacy measured as change from baseline in the IgG4-RD Responder Index at week 24; the secondary endpoint is the number of patients with treatment-emergent adverse events.

The company targets the start of the trial in the second quarter of 2027. The design is proposed, not yet registered or initiated, and it depends on an IND that has not been filed publicly. An open-label study of about 30 patients can give a useful biological and clinical signal, but steroid tapering, organ heterogeneity and the natural fluctuation of the disease will complicate interpretation, and there is no placebo arm to anchor it. The quality of the IND, of the protocol and of the biomarker plan, such as serum IgG4, plasmablasts and organ imaging, will matter as much as the start date.

11 IgG4-related disease and the treatment benchmark

IgG4-related disease is a chronic immune-mediated fibro-inflammatory condition that can affect almost any organ: pancreas, bile ducts, salivary and lacrimal glands, orbits, kidneys, lungs, aorta, retroperitoneum and lymph nodes. Untreated or under-treated, it can progress to organ failure. Spero cites an estimated 20,000 to 40,000 diagnosed patients in the United States, a typical age of onset of 50 to 70 years and organ damage at diagnosis in about 60% of patients. Those are company figures based on third-party sources, not a verified addressable-market count.

The benchmark is now high. Amgen’s Uplizna (inebilizumab, anti-CD19, B-cell depleting) became the first FDA-approved treatment for IgG4-RD on April 3, 2025. In the MITIGATE trial of 135 adults, it reduced the risk of flare by 87% versus placebo (hazard ratio 0.13); 10.3% of treated patients flared against 59.7% on placebo, and 58.8% reached flare-free, steroid-free complete remission against 22.4%. Dosing is two initial infusions and then one every six months.

Any new entrant will be judged against that profile. SP001’s argument is mechanistic: CD40L blockade acts upstream on T-cell help, germinal centers and macrophage activation without depleting B cells, which could matter for infection risk and vaccine response in older patients.

Amgen Uplizna approval release

12 Competitive landscape and pathway read-through

The direct competition in IgG4-RD moved during 2026. Zenas BioPharma reported on January 5, 2026 that obexelimab, a CD19 and FcγRIIb antibody that inhibits rather than depletes B cells, met the primary endpoint of the Phase 3 INDIGO trial with a 56% reduction in the risk of flare versus placebo (hazard ratio 0.44, p=0.0005) in 194 patients over 52 weeks, with weekly subcutaneous self-injection. On August 13, 2026 Zenas reported that the FDA had accepted the BLA, with a PDUFA target action date of May 27, 2027. Sanofi’s rilzabrutinib, an oral BTK inhibitor, is listed by Spero as in Phase 3.

Outside IgG4-RD, Sanofi’s frexalimab and Amgen’s dazodalibep target the same pathway in other diseases, which supports the target’s relevance, not SP001’s odds.

SP001 will be judged less on whether it works than on whether it works where B-cell agents do not: in patients who flare on them, or with a safety and convenience profile that matters to older patients.

Zenas INDIGO results, January 5, 2026 (SEC) · Zenas Q2 2026 release (SEC)

13 Legacy pipeline: no longer the valuation anchor

Spero stopped pursuing a Phase 2 trial of SPR206, an intravenous candidate for multidrug-resistant Gram-negative hospital infections, in March 2025, and ceased development of SPR720, an oral candidate for non-tuberculous mycobacterial lung disease, in November 2025, after 2024 interim Phase 2a data. These programs may retain contractual or residual value, but current filings do not treat them as active value drivers.

The operating center of gravity is SP001. Utebzi is a partnered economic interest that Spero will not sell itself, now largely pledged to the noteholders. The company remains lean: it reported 25 employees at December 31, 2025, 13 of them in research and development.

14 Second-quarter 2026 financial baseline

The historical revenue reflected GSK-funded development and government grants, both complete. With SP001 spending still to start, the second-quarter loss of $9.6 million understates the cost of the company Spero is becoming.

Cash at June 30 was exactly $50.774 million, up from $40.265 million at December 31, 2025. Operating cash flow in the first half was positive by $10.509 million, helped by the $25.0 million NDA milestone received in February 2026; it is not recurring cash generation. Total liabilities were $8.6 million and stockholders’ equity $44.2 million, or $0.76 per share on the 58,146,910 shares outstanding at June 30.

An illustrative bridge to the post-transaction position, using only disclosed items: $50.774 million of June cash, plus about $103.4 million of financing proceeds after the 1.5% reduction, minus the $35.0 million Innovent upfront, minus the $1.0 million Meiji milestone paid in July, gives about $118.2 million before transaction expenses and third-quarter spending. It is a reading aid, not reported cash, and the runway guidance already reflects these transactions.

Spread over the roughly three years to the second half of 2029, that balance implies an average outflow of roughly $34 to $39 million a year: enough for a small Phase 2 and a lean organization, not for a pivotal program. A positive Phase 2 would therefore likely bring a new financing decision. That is Merlintrader’s reading, not a company statement.

Form 10-Q · Q2 2026 release

15 Capital structure, dilution and runway

Spero reported 58,234,827 common shares outstanding on August 7, 2026. At June 30 there were 3,569,033 options outstanding at a weighted-average exercise price of $7.20 and 4,173,783 restricted stock units; 7.15 million more shares were available under equity plans. RSUs dilute as they vest. Since June, the company has added the August 3 grant to the new Chief Medical Officer (162,311 RSUs and options on 324,675 shares at $1.54) and the September 1 inducement grants (102,000 RSUs and 67,600 options).

Stockholders approved an increase in authorized common shares from 120 million to 240 million on June 23, 2026. No preferred shares are outstanding.

The equity window reopened on September 10. The new $300 million universal shelf allows common stock, preferred stock, debt, warrants and units; within it, the Jefferies agreement allows at-the-market sales of up to $100 million of common stock, with a commission of up to 3.0%. The prospectus illustrates the scale: at the $1.21 price of August 27, 2026, selling the full $100 million would mean about 82.6 million new shares, taking the count to about 140.8 million, and would lift net tangible book value from $0.76 to about $1.00 per share. That is an illustration of capacity, not a plan; Jefferies is not obliged to sell any amount, and Spero chooses when to sell.

The filings do not say why an ATM was registered after guiding a runway into 2029; the previous shelf dated from March 2024. The test is behavior: whether shares are sold near current prices, and in what size.

Form 8-K, August 28, 2026 · Form S-3 · SEC notice of effectiveness

16 Governance, leadership and ownership

Esther Rajavelu is President and Chief Executive Officer and also signed the Q2 10-Q as principal financial officer, so the two roles are concentrated in one person at a company that reported 25 employees at the end of 2025. Debra Zack joined as Chief Medical Officer in July 2026, bringing rheumatology training and more than 25 years of development experience in immune-mediated diseases.

The 2026 proxy statement reports GSK as owner of 9,190,606 shares, 15.9% of the 57,891,493 shares outstanding on April 1, 2026, and as the only holder above 5% identified in that filing. That is strategic alignment, but Utebzi commercial decisions sit with GSK, and its incentives at the product level are not the same as those of Spero’s common shareholders, particularly now that GSK payments service the notes first.

On regulatory matters, the Q2 10-Q reports that the SEC concluded its investigation of the company and notified Spero on January 20, 2026 that it did not intend to recommend an enforcement action. Former executives settled separately on January 16, 2026 without admitting or denying the findings.

2026 proxy statement · Form 10-Q

17 Valuation and market structure

A disciplined valuation separates five things: cash after fees and spending; the encumbered GSK stream, which belongs first to the noteholders; Spero’s retained 35% of the pledged proceeds after repayment; the early SP001 option; and the cost of developing it. The $1.05 billion Innovent milestone ceiling is a contingent payment that would only arise with success, not a current liability. Neither the shelf nor the ATM should be added to cash, and Spero should not be credited with the full Utebzi stream.

The $6.00 aggregate target is an opinion of third-party analysts compiled by Finviz, not company guidance or a Merlintrader estimate.

Short interest is low. Retail sentiment on StockTwits, read on October 2, 2026, showed a site score of 56 out of 100 labeled bullish and 2,841 watchers. Those are comments of non-professional traders and a provider score, not a share of investors or a clinical probability.

18 Ranked risks and red flags

• 1. Clinical translation: data come only from a small Sjögren’s study; an open-label IgG4-RD Phase 2 may not separate drug effect from steroid tapering.
• 2. Capital structure: 10% notes capitalized quarterly and the sale of 65% of post-repayment GSK proceeds can absorb most of the Utebzi value for years.
• 3. Commercial dependency: GSK controls the launch, the label is restricted and the royalty is 1% below $750 million of annual sales.
• 4. Timing: the IND, the trial registration and first-patient dosing can slip beyond the second quarter of 2027.
• 5. Competition: Uplizna is approved and obexelimab has a PDUFA date of May 27, 2027; the efficacy and convenience bar will be higher when SP001 reports.
• 6. Dilution: a usable $100 million ATM, 240 million authorized shares and ongoing equity awards preserve dilution risk at a low share price.
• 7. Safety: larger and longer exposure may reveal immune, infectious or thrombotic signals not visible in 24 treated patients.
• 8. Organization: about 25 people, with the CEO also principal financial officer, must build a new therapeutic area.

19 Catalyst calendar and monitoring windows

Besides the IDWeek dates, only the obexelimab PDUFA date and the contractual IND deadline are hard-dated. The Utebzi launch window and the Phase 2 start are company or partner expectations and can move.

20 Merlintrader SPRO coverage archive

Earlier Merlintrader coverage, written around the FDA decision, remains a dated record; its pre-approval framing is superseded.

21 Bottom line: funded reset, unproven new engine

Spero has materially lengthened its survival horizon. Utebzi is approved and partnered, and the July financing bought time without issuing shares. The price was high: the pledged GSK payments go to noteholders first at 10%, Spero keeps 35% only after full repayment, and the royalty below $750 million of annual sales is 1%.

SP001 is the new upside engine, a mechanistically interesting, Fc-silent anti-CD40L antibody with clean early safety and a monthly profile. It is still an early asset entering a disease where it has no patient data and where two B-cell agents may well be on the market before it reports. A proof-building approach fits: value the runway conservatively and do not double count Utebzi.